Homocysteine as a cardiovascular marker and risk factor

被引：7
作者：
Pietrzik K. [1 ]
机构：
[1] Rheinische Friedrich-Wilhelms-Universität Bonn, Institut für Ernährungswissenschaften, Bonn 53115
来源：
Clinical Research in Cardiology | 2006年 / 95卷 / Suppl 6期
关键词：
Folic acid; Homocysteine; Homocysteinemia;
D O I：
10.1007/s00392-006-1806-4
中图分类号：
学科分类号：
摘要：
In context of cardiovascular secondary prevention the D.A.C.H.-Liga (union of scientists from Germany, Austria, and Switzerland doing research on the topic homocysteine) demands that the homocysteine level should be measured and recommends a substitution of folic acid above a value of 10 μmol/l. Numerous studies have proven the therapy's positive effect. Although a threshold could not be aquired in any study there seems to be an association between the homocysteine level and an increased cardiovascular risk. Homocysteine is not only a marker, but also a reason of cardiovascular mortality and morbidity. Further detailed statements concerning homocysteine therapy can be made after completing of current research. © 2006 Steinkopff-Verlag.
引用
收藏
页码：VI/28 / VI/33
相关论文
共 14 条
  • [1] Botto L.D., Friedman J.M., Yang Q., Vortrag Anlässlich der American Heart Association's 44th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, (2004)
  • [2] Boushey C.J., Beresford S.A., Omenn G.S., Et al., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes, JAMA, 274, (1995)
  • [3] Lange H., Suryapranata H., De Luca G., Et al., Folate Therapy and In-Stent Restenosis after Coronary Stenting, N Engl J Med, 350, (2004)
  • [4] Malinow M.R., Ducimetiereb P., Lucc G., Et al., Plasma homocyst(e)ine levels and graded risk for myocardial infarction: Findings in two populations at contrasting risk for coronary heart disease, Atherosclerosis, 126, (1996)
  • [5] Malinow M.R., Duell P.B., Hess D.L., Anderson P.H., Kruger W.D., Phillipson B.E., Gluckman R.A., Block P.C., Upson B.M., Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease, N Engl J Med, 338, 15, pp. 1009-1115, (1998)
  • [6] Nygard O., Nordrehaug J.E., Refsum H., Et al., Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease, N Engl J Med, 337, (1997)
  • [7] Peterson J.C., Spence J.D., Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia, Lancet, 351, (1998)
  • [8] Schnyder G., Roffi M., Pin R., Et al., Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels, N Engl J Med, 345, (2001)
  • [9] Stampfer M.J., Malinow M.R., Willett W.C., Et al., A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians, JAMA, 268, (1992)
  • [10] Stanger O., Dierkes J., Fowler B., Geisel J., Herrmann W., Pietrzik K., Weger M., Konsensuspapier der D.A.CH.-Liga Homocystein über den rationellen klinischen Umgang mit Homocystein, Folsäure und B-Vitaminen bei kardiovaskulären und thrombotischen Erkrankungen - Richtlinen und Empfehlungen, Journal für Kardiologie, 10, 5, pp. 190-199, (2003)
12